Ergomed has unveiled a plan to acquire PSR Group BV, the specialist orphan drug CRO, for a sum of up to 5.7 million (around $6.7 million).
PSR was established in 1998 and is based in the Netherlands, and has extensive experience in rare diseases. These severe, debilitating or even life-thOriginal Article
